Navigation Links
Grant to fund development of drug candidates for rheumatoid arthritis, neurodegenerative disorders
Date:1/25/2013

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.

Derek R. Duckett, associate scientific director in TSRI's Translational Research Institute, and Peter S. Hodder, senior director of lead identification at the Translational Research Institute, will act as co-principal investigators for the three-year grant.

The project will focus on an enzyme known as ASK1, which is part of a larger family of mitogen-activated protein kinases (MAP kinases) that help control how cells respond to stress and is involved in mediating cell survival and programmed cell death (apoptosis). Genetic target validation studies have demonstrated that loss of this kinase shows remarkable efficacy in animal models of various diseases.

"While ASK1 is a highly druggable target, no tool compounds are currently available to probe its biology," Duckett pointed out. "This award will help us remedy the situation."

The new grant will allow the Scripps Florida scientists to perform a high-throughput screening campaign of the TSRI compound collection at their state-of-the-art screening facility. "Our team approach will identify the best lead molecules that will help define the roles that ASK1 plays in normal physiological processes as well as in disease states," Duckett said. "Such leads will also serve as good starting material for chemistry optimization efforts for future therapeutics."

"A very exciting prospect of this research effort is that Scripps's drug discovery compound collection will be assayed for novel inhibitors of ASK1 activity," said Hodder. "Past screening efforts with this collection yielded the antecedents of clinically relevant compounds, and the research plan we have in place bodes well for a similar outcome from this effort."


'/>"/>
Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. USDA grant advancing deadly plant disease, insect research
2. Salk Institute awarded historic $42 million grant from the Helmsley Charitable Trust
3. Childrens Hospital of Philadelphia receives federal grant to improve health care decision-making
4. AgriLife Research gets grant to crack biofuel production waste issue
5. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
6. Italian immigrants live longer
7. Grant funded to improve mothers nutrition before pregnancy and impact on baby
8. Researchers and company from Luxembourg awarded a grant from Michael J. Fox Foundation
9. University of Illinois receives grant to study ozone resistance in corn
10. Grant furthers Mercyhurst research for human pathogens in Great Lakes
11. MSU uses grant to help students master scientific mumbo jumbo
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Grant to fund development of drug candidates for rheumatoid arthritis, neurodegenerative disorders
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):
(Date:5/18/2017)... ... ... NDA Partners Chairman Carl Peck, MD , announced today that Richard Kenley, ... Pharmaceutical Development Business Unit of Cardinal Health, has joined the firm as an Expert ... Chief Operating Officer at Anaborex, Senior VP and General Manager of the San Diego ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... device compliance and commercialization, has just released version 9.0 of the Cognition Cockpit ... latest version of Cockpit,” says David Cronin, CEO of Cognition. “We’re thrilled to ...
(Date:5/18/2017)... ... May 17, 2017 , ... HOLLOWAY AMERICA, ... including food and dairy, munitions, and pharmaceutical/biotech, recently introduced The Revolution Lift™, a ... use. The improvement in technology comes on the heels of HOLLOWAY’s release of ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... example, are more likely to develop Alzheimer’s disease, while men are at greater ... for this gender-specific neuronal bias is the aim of a research program at ...
Breaking Biology Technology: